Chaoshuang Lin

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Replacement Therapy

Mesenchymal Stem Cells

Hepatitis B Virus

Electronic Health Record

Top Venues

BMC gastroenterology

Immunity, inflammation and disease

This page only lists publications with an associated author ORCID identifier.

Publications

Shufang Pan, Ying Zhang, Yingfu Zeng, Chaoshuang Lin
Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study. Immunity, inflammation and disease 12 (2) (2024)
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China. BMC gastroenterology 24 (1) (2024)
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China. BMC gastroenterology 24 (1) (2024)
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China. BMC gastroenterology 24 (1) (2024)
Shufang Pan, Ying Zhang, Yingfu Zeng, Chaoshuang Lin
Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study. Immunity, inflammation and disease 12 (2) (2024)
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China. BMC gastroenterology 24 (1) (2024)